Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective
Indian Journal of Ophthalmology · 2025
DOI: 10.4103/ijo.ijo_2198_23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Ophthalmology, 2025. Verfasst von Akshay Badakere und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Ophthalmology and Strabismus, Medical Research Foundation, Chennai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Esotropia, Botulinum Toxins, Type A, Oculomotor Muscles, Eye Movements. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Purpose
To analyze the outcomes of botulinum toxin A injection in acute acquired comitant esotropia (AACE).
Methods
This is a retrospective study that included cases diagnosed as AACE between January 2022 and February 2023. Patients who were treated with Botox and completed a minimum 3 months follow-up were included in the study. All the patients underwent a complete ophthalmic, orthoptic examination and neuroimaging. The effects of age, onset of esotropia, screen time, deviation pre injection, mode of injection (transconjunctival/ open sky) and whether injection was administered in one/both eyes on successful outcome were analysed.
Results
Twenty-seven patients (20 male, seven female) were included in the study. The median age was 10 years. The median deviation for distance and near preinjection was 35 and 40 prism diopters, respectively. Complete resolution of symptoms was noted in 18 patients (66.6%). Four patients needed prisms, two required repeat injections, and one each needed surgery and divergence therapy. Six patients developed ptosis. None of the risk factors seemed to affect outcomes.
Conclusion
Botulinum toxin injected into the medial rectus is a safe and viable option for AACE. Preinjection counseling about ptosis, recurrence needing prisms, reinjection, or surgery is important.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Ophthalmology and Strabismus, Medical Research Foundation, Chennai, Tamil Nadu, India.
- Department of Biostatistics, Sankara Nethralaya, Chennai, Tamil Nadu, India.
Zitieren
APA
Badakere, A., Badrinath, V., Dhillon, H. K., Valliappan, A., Natarajan, V., & Agarkar, S. (2025). Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_2198_23
Vancouver
Badakere A, Badrinath V, Dhillon HK, Valliappan A, Natarajan V, Agarkar S. Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective. Indian Journal of Ophthalmology. 2025. doi:10.4103/ijo.ijo_2198_23
BibTeX
@article{Badakere2025,
author = {Badakere, Akshay and Badrinath, Vibha and Dhillon, Hennaav Kaur and Valliappan, Abinaya and Natarajan, Viswanathan and Agarkar, Sumita},
title = {Botulinum toxin A as a treatment modality for acute acquired comitant esotropia – An Indian perspective},
journal = {Indian Journal of Ophthalmology},
year = {2025},
doi = {10.4103/ijo.ijo_2198_23}
}
EUVIMED